{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,17]],"date-time":"2025-06-17T04:02:16Z","timestamp":1750132936221,"version":"3.41.0"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,6,16]]},"DOI":"10.7759\/cureus.86116","type":"journal-article","created":{"date-parts":[[2025,6,16]],"date-time":"2025-06-16T10:57:07Z","timestamp":1750071427000},"source":"Crossref","is-referenced-by-count":0,"title":["Complete Remission With Fourth-Line Immunotherapy After Chemotherapy Failure in a Lung Cancer Patient With Severe Autoimmune Disease: An Unexpected Turn in Oncologic Management"],"prefix":"10.7759","author":[{"given":"Daniel","family":"Herrero Rivera","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda","family":"Soriano Segura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Javier Orlando","family":"Prato Varela","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yaroslav","family":"Brygadyr Medvid","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 Antonio","family":"L\u00f3pez Mart\u00edn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.21037\/jtd-2019-cptn-10","article-title":"Immunotherapy in patients with autoimmune disease","volume":"12","author":"Rakshit S","year":"2020","unstructured":"Rakshit S, Molina JR. Immunotherapy in patients with autoimmune disease. J Thorac Dis. 2020, 12:7032-8. 10.21037\/jtd-2019-cptn-10","journal-title":"J Thorac Dis"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cllc.2023.05.006","article-title":"Safety and efficacy of immune checkpoint inhibitors in cancer patients and preexisting autoimmune disease: a systematic review and meta-analysis in non-small-cell lung cancer","volume":"24","author":"Aung WY","year":"2023","unstructured":"Aung WY, Lee CS, Morales J, Rahman H, Seetharamu N. Safety and efficacy of immune checkpoint inhibitors in cancer patients and preexisting autoimmune disease: a systematic review and meta-analysis in non-small-cell lung cancer. Clin Lung Cancer. 2023, 24:598-612. 10.1016\/j.cllc.2023.05.006","journal-title":"Clin Lung Cancer"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2020.102687","article-title":"Immune checkpoint inhibitors therapies in patients with cancer and preexisting autoimmune diseases: A meta-analysis of observational studies","volume":"19","author":"Xie W","year":"2020","unstructured":"Xie W, Huang H, Xiao S, Fan Y, Deng X, Zhang Z. Immune checkpoint inhibitors therapies in patients with cancer and preexisting autoimmune diseases: A meta-analysis of observational studies. Autoimmun Rev. 2020, 19:102687. 10.1016\/j.autrev.2020.102687","journal-title":"Autoimmun Rev"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2024.107894","article-title":"Risk and survival of patients with non-small cell lung cancer and pre-existing autoimmune disorders receiving immune checkpoint blockade therapy: Survival analysis with inverse probability weighting from a nationwide, multi-institutional, retrospective study (NEJ047)","volume":"194","author":"Asao T","year":"2024","unstructured":"Asao T, Shukuya T, Uemura K, et al.. Risk and survival of patients with non-small cell lung cancer and pre-existing autoimmune disorders receiving immune checkpoint blockade therapy: Survival analysis with inverse probability weighting from a nationwide, multi-institutional, retrospective study (NEJ047). Lung Cancer. 2024, 194:107894. 10.1016\/j.lungcan.2024.107894","journal-title":"Lung Cancer"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.pulmoe.2020.04.019","article-title":"Are patients with autoimmune disorders eligible for immunotherapy?","volume":"27","author":"Madama D","year":"2021","unstructured":"Madama D, Pego A. Are patients with autoimmune disorders eligible for immunotherapy?. Pulmonology. 2021, 27:264-6. 10.1016\/j.pulmoe.2020.04.019","journal-title":"Pulmonology"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1111\/ene.16547","article-title":"Do immune checkpoint inhibitors affect the course of multiple sclerosis? A systematic review and meta-analysis","volume":"32","author":"Gelibter S","year":"2025","unstructured":"Gelibter S, Saraceno L, Susani E, Pirro F, Sessa M, Protti A. Do immune checkpoint inhibitors affect the course of multiple sclerosis? A systematic review and meta-analysis. Eur J Neurol. 2025, 32:e16547. 10.1111\/ene.16547","journal-title":"Eur J Neurol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2019.7310","article-title":"Preexisting Autoimmune Disease: Implications for Immune Checkpoint Inhibitor Therapy in Solid Tumors","volume":"17","author":"Kennedy LC","year":"2019","unstructured":"Kennedy LC, Bhatia S, Thompson JA, Grivas P. Preexisting Autoimmune Disease: Implications for Immune Checkpoint Inhibitor Therapy in Solid Tumors. J Natl Compr Canc Netw. 2019, 17:750-7. 10.6004\/jnccn.2019.7310","journal-title":"J Natl Compr Canc Netw"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdw443","article-title":"Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab","volume":"28","author":"Menzies AM","year":"2017","unstructured":"Menzies AM, Johnson DB, Ramanujam S, et al.. Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab. Ann Oncol. 2017, 28:368-76. 10.1093\/annonc\/mdw443","journal-title":"Ann Oncol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.7326\/M17-2073","article-title":"Use of immune checkpoint inhibitors in the treatment of patients with cancer and preexisting autoimmune disease: a systematic review","volume":"168","author":"Abdel-Wahab N","year":"2018","unstructured":"Abdel-Wahab N, Shah M, Lopez-Olivo MA, Suarez-Almazor ME. Use of immune checkpoint inhibitors in the treatment of patients with cancer and preexisting autoimmune disease: a systematic review. Ann Intern Med. 2018, 168:121-30. 10.7326\/M17-2073","journal-title":"Ann Intern Med"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1093\/noajnl\/vdaf048","article-title":"Outcomes in patients with multiple sclerosis and solid organ cancers treated with immune checkpoint inhibitors","volume":"7","author":"Hirunpattarasilp C","year":"2025","unstructured":"Hirunpattarasilp C, Fu P, Margevicius SP, et al.. Outcomes in patients with multiple sclerosis and solid organ cancers treated with immune checkpoint inhibitors. Neurooncol Adv. 2025, 7:vdaf048. 10.1093\/noajnl\/vdaf048","journal-title":"Neurooncol Adv"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.03.285","article-title":"Autoimmune diseases and immune-checkpoint inhibitors for cancer therapy: review of the literature and personalized risk-based prevention\u00a0strategy","volume":"31","author":"Haanen J","year":"2020","unstructured":"Haanen J, Ernstoff MS, Wang Y, et al.. Autoimmune diseases and immune-checkpoint inhibitors for cancer therapy: review of the literature and personalized risk-based prevention\u00a0strategy. Ann Oncol. 2020, 31:724-44. 10.1016\/j.annonc.2020.03.285","journal-title":"Ann Oncol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1507643","article-title":"Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer","volume":"373","author":"Borghaei H","year":"2015","unstructured":"Borghaei H, Paz-Ares L, Horn L, et al.. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med. 2015, 373:1627-39. 10.1056\/NEJMoa1507643","journal-title":"N Engl J Med"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.61.6870","article-title":"Pseudoprogression and immune-related response in solid tumors","volume":"33","author":"Chiou VL","year":"2015","unstructured":"Chiou VL, Burotto M. Pseudoprogression and immune-related response in solid tumors. J Clin Oncol. 2015, 33:3541-3. 10.1200\/JCO.2015.61.6870","journal-title":"J Clin Oncol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.64.0391","article-title":"Evaluation of immune-related response criteria and RECIST v1.1 in patients with advanced melanoma treated with pembrolizumab","volume":"34","author":"Hodi FS","year":"2016","unstructured":"Hodi FS, Hwu WJ, Kefford R, et al.. Evaluation of immune-related response criteria and RECIST v1.1 in patients with advanced melanoma treated with pembrolizumab. J Clin Oncol. 2016, 34:1510-7. 10.1200\/JCO.2015.64.0391","journal-title":"J Clin Oncol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2024.217241","article-title":"Immune checkpoint inhibitors rechallenge in non-small cell lung cancer: current evidence and future directions","volume":"604","author":"Gang X","year":"2024","unstructured":"Gang X, Yan J, Li X, et al.. Immune checkpoint inhibitors rechallenge in non-small cell lung cancer: current evidence and future directions. Cancer Lett. 2024, 604:217241. 10.1016\/j.canlet.2024.217241","journal-title":"Cancer Lett"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.00131","article-title":"Continuous versus 1-year fixed-duration nivolumab in previously treated advanced non-small-cell lung cancer: CheckMate 153","volume":"38","author":"Waterhouse DM","year":"2020","unstructured":"Waterhouse DM, Garon EB, Chandler J, et al.. Continuous versus 1-year fixed-duration nivolumab in previously treated advanced non-small-cell lung cancer: CheckMate 153. J Clin Oncol. 2020, 38:3863-73. 10.1200\/JCO.20.00131","journal-title":"J Clin Oncol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.08.2151","article-title":"Clinical definition of acquired resistance to immunotherapy in patients with metastatic non-small-cell lung cancer","volume":"32","author":"Schoenfeld AJ","year":"2021","unstructured":"Schoenfeld AJ, Antonia SJ, Awad MM, et al.. Clinical definition of acquired resistance to immunotherapy in patients with metastatic non-small-cell lung cancer. Ann Oncol. 2021, 32:1597-607. 10.1016\/j.annonc.2021.08.2151","journal-title":"Ann Oncol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/374624-complete-remission-with-fourth-line-immunotherapy-after-chemotherapy-failure-in-a-lung-cancer-patient-with-severe-autoimmune-disease-an-unexpected-turn-in-oncologic-management","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,16]],"date-time":"2025-06-16T10:57:07Z","timestamp":1750071427000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/374624-complete-remission-with-fourth-line-immunotherapy-after-chemotherapy-failure-in-a-lung-cancer-patient-with-severe-autoimmune-disease-an-unexpected-turn-in-oncologic-management"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,16]]},"references-count":17,"URL":"https:\/\/doi.org\/10.7759\/cureus.86116","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6,16]]}}}